APA (7th ed.) Citation

Heymach, J., Hanrahan, E., Mann, H., Langmuir, P., Natale, R., Johnson, B., . . . Ryan, A. (2008). Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC.

Chicago Style (17th ed.) Citation

Heymach, J., E. Hanrahan, H. Mann, P. Langmuir, R. Natale, B. Johnson, R. Herbst, and A. Ryan. Baseline VEGF as a Potential Predictive Biomarker of Vandetanib Clinical Benefit in Patients with Advanced NSCLC. 2008.

MLA (9th ed.) Citation

Heymach, J., et al. Baseline VEGF as a Potential Predictive Biomarker of Vandetanib Clinical Benefit in Patients with Advanced NSCLC. 2008.